FDA approves Teva's Cinqair for asthma

FDA approved Cinqair reslizumab from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) as an add-on maintenance treatment of severe asthma in

Read the full 192 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE